glp 1 novo nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk is slashing GLP-1
Description
Galaris, N.K
Su CJ, Shen Z, Cui RX, et al
Exendin-4 stimulates -cell proliferation and inhibits -cell apoptosis in wildtype mice but not in mice with -cell specific inactivation of Pdx1 [542]
This recommendation reflects a paradigm shift from a glucose-centric model toward a more comprehensive cardiometabolic approach
Early findings from higher-dose oral semaglutide trials show more promising weight-loss results than the currently approved 14 mg tablet
Within this dynamic trajectory, structured exercise interventions may play a pivotal role in sustaining weight loss, enhancing metabolic control, and potentially attenuating weight regain after drug discontinuation
